The top 10 biopharma pipeline blowups, setbacks and snafus for H2 2019
Every 6 months, as longtime followers will know, I like to list the top 10 disasters in clinical R&D. And it seems like every new round-ups the ante a little more on just what qualifies for a top blooper of the year.
H2 2019 is certainly a standout, with a Big Pharma data scandal, a couple of blockbuster M&A busts and a whole run of Alzheimer’s setbacks to contemplate as we watch the Biogen saga play out. Not only does the Alzheimer’s field continue to crater, but we watched antibiotics come apart in the last 6 months of 2019.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters